The global burden of mental, neurological and substance use disorders: An analysis from the Global Burden of Disease Study 2010.
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The Global Burden of Disease Study 2010 (GBD 2010), estimated that a substantial proportion of the world's disease burden came from mental, neurological and substance use disorders. In this paper, we used GBD 2010 data to investigate time, year, region and age specific trends in burden due to mental, neurological and substance use disorders. METHOD: For each disorder, prevalence data were assembled from systematic literature reviews. DisMod-MR, a Bayesian meta-regression tool, was used to model prevalence by country, region, age, sex and year. Prevalence data were combined with disability weights derived from survey data to estimate years lived with disability (YLDs). Years lost to premature mortality (YLLs) were estimated by multiplying deaths occurring as a result of a given disorder by the reference standard life expectancy at the age death occurred. Disability-adjusted life years (DALYs) were computed as the sum of YLDs and YLLs. RESULTS: In 2010, mental, neurological and substance use disorders accounted for 10.4% of global DALYs, 2.3% of global YLLs and, 28.5% of global YLDs, making them the leading cause of YLDs. Mental disorders accounted for the largest proportion of DALYs (56.7%), followed by neurological disorders (28.6%) and substance use disorders (14.7%). DALYs peaked in early adulthood for mental and substance use disorders but were more consistent across age for neurological disorders. Females accounted for more DALYs in all mental and neurological disorders, except for mental disorders occurring in childhood, schizophrenia, substance use disorders, Parkinson's disease and epilepsy where males accounted for more DALYs. Overall DALYs were highest in Eastern Europe/Central Asia and lowest in East Asia/the Pacific. CONCLUSION: Mental, neurological and substance use disorders contribute to a significant proportion of disease burden. Health systems can respond by implementing established, cost effective interventions, or by supporting the research necessary to develop better prevention and treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which is significant contributor to the global burden of disease [7, 43].”
From The global prevalence of postpartum psychosis: a systematic review (2017) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Anxiety disorders cause 10.4% of the Disability Adjusted Life Years (DALYs) lost due to neurological, mental, substance use disorders and account for 1.1% of the global burden of disease worldwide, that is a total of 26,800,000 DALYs worldwide (Whiteford, Ferrari, Degenhardt, Feigin, & Vos, 2015).”
From Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries (2018) · cites this paper as Whiteford, Ferrari, Degenhardt, Feigin, & Vos, 2015
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“As described above, postpartum psychosis is a key marker for the risk of future affective disorder”
From The global prevalence of postpartum psychosis: a systematic review (2017) · cites this paper as [43]
Experimental — accuracy not yet measuredIn the citing paper
“In 2010, mental, neurological and substance abuse disorders accounted for 10.4% of all disability-adjusted life-years globally.21”
From Climate change, climate-related disasters and mental disorder in low- and middle-income countries: a scoping review (2021) · cites this paper as [21]
In the citing paper
“Recent prevalence estimates indicate 10.7% of the world’s population live with a mental health disorder, and the number of years lived with a mental health disorder has increased by 13.5% from 2007 to 2017”
From Explaining adults’ mental health help-seeking through the lens of the theory of planned behavior: A scoping review (2022) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Self-citationLim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Self-citationMurray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888 · cited 7×
“Overall, GBD 2010 findings highlighted a shift in burden from communicable to noncommunicable diseases and from YLLs to YLDs [1,11].”
InfluentialSelf-citationVos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Self-citationWorld Population Prospects The 2006 Revision
Zlotnik, H. (2007) · United Nations eBooks · Cited by 7,970
(1996) · Cited by 6,884
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Self-citationDiagnostic and Statistical Manual of Mental Disorders ( DSM ‐ IV ‐ TR )
Segal, D. L. (2010) · The Corsini Encyclopedia of Psychology · doi:10.1002/9780470479216.corpsy0271 · Cited by 4,666
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
Self-citation
Cited by
Items 401–500 of 1,000
Hintsa, T., Wesołowska, K., Elovainio, M. J., Strelau, J., Pulkki-Råbäck, L., & Keltikangas‐Järvinen, L. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.056 · Cited by 26
Crouse, J. J., Chitty, K. M., Iorfino, F., White, D., Nichles, A., Zmicerevska, N., Guastella, A. J., Moustafa, A. A., Hermens, D. F., Scott, E. M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210877 · Cited by 25
Triana, R., Keliat, B. A., Wardani, I. Y., Sulistiowati, N. M. D., & Veronika, M. A. (2019) · Enfermería Clínica · doi:10.1016/j.enfcli.2019.04.096 · Cited by 24
“Mental disorders are known to begin at the productive age about 10--29 years.(2,3) In Indonesia, 14 million people over the age of 15 suffer from mental disorders.”
BackgroundLevy, R., Mathai, M., Chatterjee, P., Ongeri, L., Njuguna, S., Onyango, D., Akena, D. H., Rota, G., Otieno, A., Neylan, T. C., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2395-x · Cited by 26
Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients
Martinotti, G., Negri, A., Schiavone, S., Montemitro, C., Vannini, C., Baroni, G., Pettorruso, M., De‐Giorgio, F., Giorgetti, R., Verrastro, V., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00879 · Cited by 24
“In 2017, an estimated 271 million people worldwide had used psychoactive substances during the previous year—a number 30% higher than that in 2009 (2)— putting substance use disorders (SUDs) among the leading causes of disability worldwide (3).”
BackgroundDevelopmental exposure to vitamin D deficiency and subsequent risk of schizophrenia
Albiñana, C., Boelt, S. G., Cohen, A. S., Zhu, Z., Musliner, K. L., Vilhjálmsson, B. J., & McGrath, J. J. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.06.004 · Cited by 26
“Neurodevelopmental disorders such as schizophrenia and autism spectrum disorders (ASD) are major contributors to the burden of disease (Whiteford et al., 2015).”
Smith, A. W., Jones, J., Houghton, L. J., & Duffell, T. (2016) · International Journal of Sport Policy and Politics · doi:10.1080/19406940.2016.1230554 · Cited by 27
Hughes-Morley, A., Hann, M., Fraser, C., Meade, O., Lovell, K., Young, B., Roberts, C., Cree, L., More, D., O’Leary, N., et al. (2016) · Trials · doi:10.1186/s13063-016-1718-1 · Cited by 27
Macgregor, A., Brown, M. J., & Stavert, J. (2019) · Health & Social Care in the Community · doi:10.1111/hsc.12749 · Cited by 26
“This includes women, young people, people with intellectual disabilities, individuals from lower socioeconomic groups, and those who are unemployed, homeless, and have problem substance use (Semrau et al, 2015; Howlett et al, 2015; Whiteford et al, 2015; Winkler et al, 2017).”
BackgroundRoelandt, J.-L., Baleige, A., Koenig, M., Demassiet, V., Agoub, M., Barikova, V., Benmessaoud, D., Brunet, F., Carta, M.-G., Castelpietra, G., et al. (2020) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-020-01836-6 · Cited by 23
Pihlaja, S., Lahti, J. M. T., Lipsanen, J. O., Ritola, V., Gummerus, E.-M., Stenberg, J., & Joffe, G. (2020) · Journal of Medical Internet Research · doi:10.2196/15732 · Cited by 25
Hou, Y.-R., Masoudi, M., Chadala, A., & Olszewska-Guizzo, A. (2020) · Remote Sensing · doi:10.3390/rs12213517 · Cited by 23
Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain
Einarson, T. R., Bereza, B. G., Llinares, I. G., Moro, B. G. M., Tedouri, F., & Impe, K. V. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1351370 · Cited by 25
Maj, A., Michalak, N., Graczykowska, A., & Andersson, G. (2023) · Internet Interventions · doi:10.1016/j.invent.2023.100654 · Cited by 22
Kim, J.-S., Kwon, R., Yun, H., Lim, G., Woo, K.-S., & Kim, I. (2024) · Scandinavian Journal of Work Environment & Health · doi:10.5271/sjweh.4182 · Cited by 23
“The burden of mental disorders peaks among middle-aged adults, the main working-age population ( 3 ), and suicide mortality has increased in this group (4).”
BackgroundHobbs, M., Deng, B., Woodward, L. J., Marek, L., McLeod, G., Sturman, A. P., Kingham, S., Ahuriri‐Driscoll, A., Eggleton, P., Campbell, M. H., et al. (2025) · Environmental Research · doi:10.1016/j.envres.2025.121148 · Cited by 24
“…outcomes to adolescence is especially crucial considering the human and societal cost of poor mental health and reduced human potential (Whiteford et al., 2015), the global shift toward urban living (World Health Organisation, 2016) and the backdrop of emissions-induced climate change…”
Nanozymes: Innovative Therapeutics in the Battle Against Neurodegenerative Diseases
Duţă, C., Dogaru, C. B., Muscurel, C., & Stoian, I. A.-M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083522 · Cited by 24
“The accumulation of myeloid-derived suppressor cells (MDSCs) contributes to an increase in the inflammatory response, which, in turn, aggravates the clinical features and symptoms of MS [187].”
Frohlich, J. R., Rapinda, K. K., Schaub, M. P., Wenger, A., Baumgartner, C., Johnson, E. A., O’Connor, R. M., Vincent, N., Blankers, M., Ebert, D. D., et al. (2018) · JMIR Research Protocols · doi:10.2196/11298 · Cited by 24
Ottesen, N. M., Meluken, I., Scheike, T., Kessing, L. V., Miskowiak, K. W., & Vinberg, M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00401 · Cited by 22
Improving Access to Psychological Therapies in Spain: From IAPT to PsicAP
Vindel, A. C., Ruiz‐Rodríguez, P., Moriana, J. A., Medrano, L. A., González‐Blanch, C., Aguirre, E., & Muñoz‐Navarro, R. (2022) · Psicothema · doi:10.7334/psicothema2021.113 · Cited by 26
Pang, X., Zhu, D., Suyong, Y. A. N. G., Ke, X., Wang, J.-B., Wang, J., Schöllhorn, W. I., & Yin, Y. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.941719 · Cited by 23
“As a global public health problem (Whiteford et al., 2015), substance use disorder (SUD) has elicited increasing concern.”
BackgroundKwobah, E., Turissini, M., Barasa, J., Kimaiyo, M., Okeyo, L., Araka, J., Njiriri, F., Matundura, R., & Jaguga, F. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09481-w · Cited by 29
Hong, S., Lu, B., Wang, S., & Jiang, Y. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06577-x · Cited by 23
Carbohydrate Nanoparticles for Brain Delivery
Lalatsa, A., & Barbu, E. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.05.004 · Cited by 24
Zanatta, G., Nunes, G. D., BEZERRA, E. M., da COSTA, R. F., Martins, A. M. C., Caetano, E. W. S., Freire, V. N., & Gottfried, C. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00074 · Cited by 25
Exome sequencing in large, multiplex bipolar disorder families from Cuba
Maaser, A., Forstner, A. J., Strohmaier, J., Hecker, J., Ludwig, K. U., Sivalingam, S., Streit, F., Degenhardt, F., Witt, S. H., Reinbold, C. S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205895 · Cited by 22
“The lifetime prevalence of BD in the general population is around 1% [2], and the World Health Organization ranks BD among the top 10 leading causes of disease burden for the age group 15-to-44 years (The global burden of disease: 2004 update) [3, 4].”
BackgroundVeldman, E. R., Svedberg, M. M., Svenningsson, P., & Lundberg, J. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.02.011 · Cited by 23
Luciana, M. M., & Ewing, S. W. F. (2015) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2015.10.005 · Cited by 26
“In a recent study and metaanalytic review, Weiland et al. (2015) concluded, in fact, that daily marijuana use was not associated with morphometric brain changes in adolescents or adults.”
Luitel, N. P., Garman, E. C., Jordans, M. J. D., & Lund, C. (2019) · BMC Public Health · doi:10.1186/s12889-019-7663-7 · Cited by 21
Crouse, J. J., Chitty, K. M., Iorfino, F., Carpenter, J. S., White, D., Nichles, A., Zmicerevska, N., Guastella, A. J., Scott, E. M., Lee, R. S. C., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0726-9 · Cited by 21
Determinants of Telehealth Service Use among Mental Health Patients: A Case of Rural Louisiana
Sizer, M. A., Bhatta, D., Acharya, B., & Paudel, K. P. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116930 · Cited by 23
Xu, T., Huang, Z., Huang, Y., Wang, S., Zhang, X., Zhu, Y., Zhu, Y., Cheng, D., Fu, Y., Zhang, X., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-16008-9 · Cited by 23
Disruption of Ninjurin1 Leads to Repetitive and Anxiety-Like Behaviors in Mice
Le, H.-A., Ahn, B., Lee, H., Shin, A., Chae, S., Lee, S.-Y., Shin, M., Lee, E.-J., Cha, J.-H., Son, T., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0207-6 · Cited by 20
Sajjadi, H., Shushtari, Z. J., Mahboubi, S., Rafiey, H., & Salimi, Y. (2018) · Public Health · doi:10.1016/j.puhe.2018.01.004 · Cited by 21
Educational policies and social inequality in well-being among young adults
Högberg, B. (2019) · British Journal of Sociology of Education · doi:10.1080/01425692.2019.1576119 · Cited by 28
Hinrichsen, C., Koushede, V., Madsen, K. R., Nielsen, L., Ahlmark, N., Santini, Z. I., & Meilstrup, C. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17165819 · Cited by 21
Mansourian, M., Khademi, S., & Marateb, H. R. (2021) · Diagnostics · doi:10.3390/diagnostics11030393 · Cited by 22
Jacinto, M., Frontini, R., Matos, R. M. N., & Antunes, R. (2021) · Healthcare · doi:10.3390/healthcare9081047 · Cited by 21
Lindert, J., Bilsen, J. J. R., & Jakubauskienė, M. (2017) · European Journal of Public Health · doi:10.1093/eurpub/ckx163 · Cited by 21
Rozario, S. S., & Masho, S. W. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy065 · Cited by 24
Wang, Y., Liu, J., & Zhou, H. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104827 · Cited by 23
Stress-induced generalization of negative memories is mediated by an extended hippocampal circuit
Ren, L. Y., Meyer, M. A. A., Grayson, V. S., Gao, P., Guedea, A. L., & Radulović, J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01174-4 · Cited by 22
Oyenubi, A., Kim, A. W., & Kollamparambil, U. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.072 · Cited by 22
de Pinho, C. S. N., Santana, R. D., Campos, E. D. M., & Neto, R. D. J. P. (2022) · AIDS Care · doi:10.1080/09540121.2022.2100866 · Cited by 20
“Such data seem to agree with studies that show the marked impact mental disorders have on the global burden of diseases (Whiteford et al., 2015).”
ResultYang, W., Yin, H. J., Wang, Y., Wang, Y., Li, X., Wang, C., Liu, P., & Hu, Y. (2023) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2022.06.012 · Cited by 22
Carpallo-González, M., Muñoz‐Navarro, R., González‐Blanch, C., & Vindel, A. C. (2023) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2023.100379 · Cited by 21
“8% in the MA conducted by Wierzbicki and Pekarik (1993) and 35.”
BackgroundPrimary psychosis and Borna disease virus infection in Lithuania: a case control study
Zaliunaite, V., Steiblienė, V., Bode, L., Podlipskytė, A., Bunevičius, R., & Ludwig, H. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1087-z · Cited by 20
Efficacy and Tolerability of Clozapine versus Quetiapine in Treatment-resistant Schizophrenia
Kumar, M., Chavan, B. S., Sidana, A. K., & Das, S. C. (2017) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_111_17 · Cited by 20
“5% of the disability-adjusted life years.([1]) Antipsychotic is the main-stay of treatment for people with schizophrenia, and yet approximately one-fifth to one-third of patients with this disorder are resistant to drug treatment.”
BackgroundSorkin, D. H., Rizzo, S., Biegler, K. A., Sim, S. E., Nicholas, E. A., Chandler, M., Ngo‐Metzger, Q., Paigne, K., Nguyen, D. V., & Mollica, R. F. (2019) · Medical Care · doi:10.1097/mlr.0000000000001036 · Cited by 21
Jankovic, M. J., Kapadia, P., & Krishnan, V. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224856 · Cited by 26
Bromberg, D. J., Paltiel, A. D., Busch, S. H., & Pachankis, J. E. (2020) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-020-01938-1 · Cited by 25
Dies, M. A., Sánchez‐Ortí, J. V., Correa‐Ghisays, P., Balanzá‐Martínez, V., Vila‐Francés, J., Selva‐Vera, G., Correa-Estrada, P., Forés-Martos, J., Valenzuela, C. S. M., Monfort-Pañego, M., et al. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.525231 · Cited by 21
Rational drug discovery design approaches for treating Parkinson’s disease
der Schyf, C. J. V. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041495 · Cited by 20
“7% of mental, neurological and substance abuse DALYs [150].”
BackgroundInfluentialHensel, J. M., Shaw, J., Ivers, N. M., Desveaux, L., Vigod, S. N., Bouck, Z., Onabajo, N., Agarwal, P., Mukerji, G., Yang, R., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2030-x · Cited by 21
Alanazi, A., Alqahtani, M. Μ., Pavela, G., Ford, E. W., Leventhal, A. M., & Hendricks, P. S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17238799 · Cited by 22
“The evidence supporting a link between mental health functioning and the use of addictive substances, including nicotine [42,43], prompted us to test whether mental health functioning is associated with e-cigarette use in young adults with asthma.”
BackgroundSystematic Quality Improvement and Metabolic Monitoring for Individuals Taking Antipsychotic Drugs
Soda, T., Richards, J., Gaynes, B. N., Cueva, M., Laux, J. P., McClain, C., Frische, R. M., Lindquist, L. K., Cuddeback, G. S., & Jarskog, L. F. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000155 · Cited by 22
Reardon, C. L., Gorczynski, P. F., Hainline, B. W., Hitchcock, M., Purcell, R., Rice, S., & Walton, C. C. (2021) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2021.05.010 · Cited by 27
Gandy, M., Heriseanu, A. I., Dudeney, J. E., Bisby, M. A., Scott, A. J., Fisher, A. C., Hathway, T., Karin, E., Titov, N., & Dear, B. F. (2021) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2021.08.013 · Cited by 22
Network modeling of major depressive disorder symptoms in adult women
Moradi, S., Falsafinejad, M. R., Delavar, A., Tabar, V. R., Borjali, A., Aggen, S. H., & Kendler, K. S. (2022) · Psychological Medicine · doi:10.1017/s0033291722002604 · Cited by 21
Burden and Indirect Costs of Mental Disorders
Razzouk, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-55266-8_25 · Cited by 19
Pigeon-Gagné, É., Hassan, G., Yaogo, M., & Ridde, V. (2017) · International Journal for Equity in Health · doi:10.1186/s12939-017-0633-8 · Cited by 23
Farahzadi, M.-H., Moazen-Zadeh, E., Razaghi, E., Zarrindast, M.-R., Bidaki, R., & Akhondzadeh, S. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118817166 · Cited by 18
Akiba, C. F., Go, V. F.-L., Mwapasa, V., Hosseinipour, M. C., Gaynes, B. N., Amberbir, A., Udedi, M. M., & Pence, B. W. (2019) · International Journal of Mental Health Systems · doi:10.1186/s13033-019-0327-2 · Cited by 20
“0 9/12/2017 Mental health disorders, including depressive disorders, anxiety disorders, schizophrenia, and bi-polar disorder, account for nearly one-third of years lived with disability (YLDs), making them the leading cause of YLDs and the fifth leading cause of disability adjusted life years (DALYs) globally [1, 2].”
BackgroundPhytochemicals as therapeutic interventions in neurodegenerative diseases
Kavitha, R. V., Kumar, J. R., Egbuna, C., & Ifemeje, J. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817890-4.00010-x · Cited by 28
Nielsen, K., & Ward, T. J. (2020) · Theory & Psychology · doi:10.1177/0959354320906462 · Cited by 20
“Mental disorders negatively affect the lives of hundreds of millions of individuals and represent a significant proportion of the global burden of disease (Kessler et al., 2009; Walker et al., 2015; Whiteford et al., 2015; World Health Organization, 2019).”
BackgroundWerneck, A. O., Christófaro, D. G. D., Ritti‐Dias, R. M., Cucato, G. G., Stubbs, B., Oyeyemi, A. L., Conceição, R. D. O., Santos, R. D., & Bittencourt, M. S. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112967 · Cited by 21
Buttazzoni, A. N., Tariq, U., Thompson-Haile, A., Burkhalter, R., Cooke, M. J., & Minaker, L. M. (2020) · Health Education & Behavior · doi:10.1177/1090198120965509 · Cited by 22
“Globally, anxiety and mood disorders are the most prevalent health conditions (Whiteford et al., 2015).”
BackgroundMahajan, S., Singh, D., Sharma, R., Singh, G., & Bedi, N. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-020-01882-y · Cited by 19
Giusto, A. M., Johnson, S. L., Lovero, K. L., Wainberg, M. L., Rono, W., Ayuku, D., & Puffer, E. S. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103291 · Cited by 21
Ren, X., Wang, S., He, Y. L., Lian, J., Lu, Q., Gao, Y., & Wang, Y. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.585597 · Cited by 19
“There are more than 8 million deaths and approximate 350 million people suffering from depressive symptoms to different degree every year (Whiteford et al., 2010; Walker et al., 2015; Vigo et al., 2016; World Health Organization, 2017).”
BackgroundHartwell, E. E., Merikangas, A. K., Verma, S. S., Ritchie, M. D., Kranzler, H. R., & Kember, R. L. (2021) · Addiction Biology · doi:10.1111/adb.13099 · Cited by 19
Li, C., Yang, F., Yang, B. X., Chen, W.-C., Wang, Q., Huang, H., Liu, Q., Luo, D., Wang, X. Q., & Ruan, J. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04252-z · Cited by 19
Angstman, K. B., Wi, C., Williams, M. D., Bohn, B. A., & Garrison, G. M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.05.098 · Cited by 20
Adu, Oudshoorn, Anderson, Marshall, Stuart, & Stanley (2021) · Issues in Mental Health Nursing · doi:10.1080/01612840.2021.1936710 · Cited by 18
Adewuya, A. O., Adewumi, T., Momodu, O., Olibamoyo, O., Adesoji, O., Adegbokun, A., Adeyemo, S., Manuwa, O., & Adegbaju, D. (2019) · Psychological Medicine · doi:10.1017/s0033291718002970 · Cited by 18
“Depression substantially impairs quality of life, social functioning, and workforce participation among people with the disease, their family members, and their communities (GBD, 2013; Whiteford et al., 2015).”
BackgroundBayes, J., Schloss, J. M., & Sibbritt, D. W. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520004699 · Cited by 19
Cuoco, S., Carotenuto, I., Cappiello, A., Bisogno, R., Picillo, M., Pellecchia, M. T., Barone, P., & Erro, R. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05784-0 · Cited by 18
Zheng, P., Yang, H., & Wang, Z. (2022) · Medicine · doi:10.1097/md.0000000000029841 · Cited by 18
Risk correlates for physical-mental multimorbidities in South Africa: a cross-sectional study
Petersen, I., Rathod, S. D., Kathree, T., Selohilwe, O., & Bhana, A. (2017) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796017000737 · Cited by 22
“%) globally (Whiteford et al. 2015).”
Tirfessa, K., Lund, C., Medhin, G., Hailemichael, Y., Habtamu, K., Fekadu, A., & Hanlon, C. (2019) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-019-01709-7 · Cited by 21
Uslu, F. İ., Gökçal, E., & Gelişin, Ö. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.014 · Cited by 18
Why We Come: Clubhouse Members Seek Connection, Purpose and Meaning
Pernice, F. M., Price, M., & Rice, K. (2020) · Community Mental Health Journal · doi:10.1007/s10597-020-00685-6 · Cited by 20
Arage, G., Belachew, T., Abera, M., Abdulhay, F., Abdulahi, M., & Abate, K. H. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038977 · Cited by 20
Aryutova, K., Paunova, R., Kandilarova, S., Todeva-Radneva, A., & Stoyanov, D. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i5.169 · Cited by 18
O'Donnell, A. J., Schmidt, C. S., Beyer, F. R., Schrietter, M., Anderson, P., Jané‐Llopis, E., Kaner, E., & Schulte, B. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.11.039 · Cited by 22
Tseng, H.-J., Lu, C., Jeng, J., Cheng, C., Chu, J.-W., Chen, M., Bai, Y., Tsai, S., Su, T., & Li, C. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.210131 · Cited by 19
Designing clinically useful psychopharmacological trials: challenges and ways forward
Chevance, A., Ravaud, P., Cornelius, V. R., Mayo‐Wilson, E., & Furukawa, T. A. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00041-4 · Cited by 24
Serum 25-hydroxyvitamin D and mental health in young Australian women: Results from the Safe-D study
Callegari, E. T., Reavley, N. J., Gorelik, A., Garland, S. M., & Wark, J. D. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.002 · Cited by 22
Wolfson, C. M., Fereshtehnejad, S., Pasquet, R., Postuma, R. B., & Keezer, M. R. (2018) · European Journal of Neurology · doi:10.1111/ene.13823 · Cited by 18
Chen, C., & Nakagawa, S. (2018) · Challenges · doi:10.3390/challe9020041 · Cited by 18
“Already, neurological and psychiatric disorders have become a leading cause of the global burden of disease [60,61], with huge economic losses and health care costs reducing resources available to manage environmental damage and pollution control.”
BackgroundThe Emerging Neurobiology of Bipolar Disorder
Harrison, P. J., Geddes, J. R., & Tunbridge, E. M. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17309 · Cited by 21
Implications of Drug Use Disorders on Spine Surgery
Ferari, C. S., Katsevman, G. A., Dekeseredy, P., & Sedney, C. L. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2019.12.177 · Cited by 19
Suicidal Behavior and Club Drugs in Young Adults
Martinotti, G., Schiavone, S., Negri, A., Vannini, C., Trabace, L., Berardis, D. D., Pettorruso, M., Sensi, S. L., & Giannantonio, M. D. (2021) · Brain Sciences · doi:10.3390/brainsci11040490 · Cited by 20
“In particular, clubbers and recreational drug users are younger and younger and differ significantly from the “drug addicts” of the past [2,31,32].”
BackgroundOpiyo, E., Ongeri, L., Rota, G., Verdeli, H., Neylan, T., & Meffert, S. (2016) · Journal of Clinical Psychology · doi:10.1002/jclp.22359 · Cited by 17
Using NIATx strategies to implement integrated services in routine care: a study protocol
Ford, J. H., Osborne, E. L., Assefa, M. T., McIlvaine, A. M., King, A. M., Campbell, K. M., & McGovern, M. P. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3241-4 · Cited by 17
User Reviews of Depression App Features: Sentiment Analysis
Meyer, J. M., & Okuboyejo, S. R. (2021) · JMIR Formative Research · doi:10.2196/17062 · Cited by 18
Microfiber transport characterization in human nasal cavity – Effect of fiber length
Li, J., Ma, J., Dong, J., Yang, W. H., Ahmadi, G., Tu, J. Y., & Tian, L. (2021) · Journal of Aerosol Science · doi:10.1016/j.jaerosci.2021.105908 · Cited by 17
Non-communicable disease burden among inpatients at a rural district hospital in Malawi
Olds, P., Kachimanga, C., Talama, G. C., Mailosi, B. G. D., Ndarama, E. P. L., Totten, J., Musinguzi, N., Hangiwa, D., Bukhman, G., & Wroe, E. B. (2023) · Global Health Research and Policy · doi:10.1186/s41256-023-00289-z · Cited by 22
Gender differences in susceptibility to schizophrenia: Potential implication of neurosteroids
Huang, Y., Hung, C., Lin, P., Lee, Y., Wu, C., Hsu, S., Chen, C.-C., Chong, M., Lin, C., & Wang, L. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.06.017 · Cited by 19
Bhad, R., Gupta, R., & Balhara, Y. P. S. (2019) · Journal of Ethnicity in Substance Abuse · doi:10.1080/15332640.2018.1542528 · Cited by 17
Metadata
- Authors
- Whiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V., & Vos, T.
- Affiliations
- The University of Queensland (AU)
- The University of Melbourne (AU)
- Auckland University of Technology (NZ)
- University of Washington (US)
- Corresponding author
- Whiteford, Harvey A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-02-06
- Volume
- 10
- Issue
- 2
- Pages
- e0116820
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4320057
- OpenAlex
- W2006103193
- Semantic Scholar
- 29fdb08fe359a077ba5ecfea8813becf7defce8c
- Cited by
- 1,175
- References
- 47
- Citations by year
- 2026: 34 · 2025: 63 · 2024: 83 · 2023: 111 · 2022: 121 · 2021: 142 · 2020: 145 · 2019: 143 · 2018: 123 · 2017: 113 · 2016: 66 · 2015: 29
- FWCI
- 180.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Tuwhera (Auckland University of Technology) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bill and Melinda Gates Foundation
- Australian Government
- University of New South Wales
- Medical Research Council
- National Health and Medical Research Council (1041742)
- National Drug and Alcohol Research Centre
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Global Health and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- mental illness, neurological disorders, substance use disorders, global burden of disease, disability-adjusted life years, years lived with disability, prevalence trends, sex differences, age differences, regional variation, schizophrenia, Parkinson's disease, epilepsy
- MeSH terms
- Age Factors, Bayes Theorem, Mental Disorders, Female, Geography, Humans, Male, Nervous System Diseases, Regression Analysis, Time Factors, Global Health, Prevalence, Cost of Illness, Quality-Adjusted Life Years, Substance-Related Disorders, Mortality, Premature
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.